Evaluation series on safety and efficacy of nutritional supplements in newly diagnosed hyperglycemia: A placebo-controlled, randomized study

Conclusions: Nearly 1% point reduction in HbA1c at week 12 with PreCrea ® is comparable with most first-line glucose-lowering drugs. The safety and tolerability of PreCrea ® highlights its potential as a first-line therapy in newly detected hyperglycemia.

Source: North American Journal of Medical Sciences - February 23, 2016 Category: Journals (General) Authors: Hemant ThackerGanapati BantwalSunil JainSanjay KalraShailaja KaleBanshi SabooJugal B GuptaSakthivel Sivam Source Type: research